Bevacizumab biobetter - Prestige BioPharmaAlternative Names: Avastin biobetter - Prestige BioPharma; PBP 1503
Latest Information Update: 18 Jan 2017
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Jan 2017 Preclinical trials in Solid tumours (Second-line therapy or greater, Treatment-resistant) in Singapore (Parenteral) before January 2017 (Prestige BioPharma pipeline, January 2017)